rilzabrutinib
Phase 2Active 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Warm Autoimmune Hemolytic Anemia (wAIHA)
Conditions
Warm Autoimmune Hemolytic Anemia (wAIHA)
Trial Timeline
Dec 7, 2021 → Dec 31, 2029
NCT ID
NCT05002777About rilzabrutinib
rilzabrutinib is a phase 2 stage product being developed by Sanofi for Warm Autoimmune Hemolytic Anemia (wAIHA). The current trial status is active. This product is registered under clinical trial identifier NCT05002777. Target conditions include Warm Autoimmune Hemolytic Anemia (wAIHA).
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07007962 | Phase 3 | Recruiting |
| NCT07216079 | Phase 3 | Active |
| NCT05002777 | Phase 2 | Active |
| NCT06444191 | Phase 1 | Completed |
| NCT06444204 | Phase 1 | Completed |
| NCT03395210 | Phase 2 | Completed |
Competing Products
12 competing products in Warm Autoimmune Hemolytic Anemia (wAIHA)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ianalumab + Placebo | Novartis | Phase 3 | 77 |
| rituximab (Mabthera®) + Placebo | Roche | Phase 3 | 77 |
| Isatuximab SAR650984 | Sanofi | Phase 2 | 51 |
| parsaclisinib + placebo | Incyte | Phase 3 | 74 |
| RVT-1401 680 mg/weekly + RVT-1401 340 mg/weekly | Immunovant | Phase 2 | 49 |
| HMPL-523(300mg PO QD) + Placebo | HUTCHMED | Phase 2/3 | 60 |
| APL-2 | Apellis Pharmaceuticals | Phase 2 | 47 |
| Obexelimab + Obexelimab | Zenas BioPharma | Phase 3 | 72 |
| ANX005 | Annexon | Phase 2 | 47 |
| Fostamatinib 150 mg bid | Rigel Pharmaceuticals | Phase 2 | 44 |
| Fostamatinib disodium | Rigel Pharmaceuticals | Phase 3 | 69 |
| Fostamatinib disodium + Placebo | Rigel Pharmaceuticals | Phase 3 | 69 |